Other · developed by TScan Therapeutics
TSC-203-A0201 is an investigational agent studied as a monotherapy and in combination with TSC-204-A0101, TSC-201-B0702 and TSC-202-A0201 in escalating doses. It is being studied in HPV-related cancers, including cervical cancer, head and neck cancer and other HPV-associated malignancies, as well as melanoma, non-small cell carcinoma and ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05973487 | Phase 1 | Head and Neck Cancer | Active not recruiting | TCRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Anogenital CancersCervical CancerHead and Neck CancerHPV - Anogenital Human Papilloma Virus InfectionHPV Positive Oropharyngeal Squamous Cell CarcinomaHPV-Associated Vaginal AdenocarcinomaHPV-Related AdenocarcinomaHPV-Related Adenosquamous CarcinomaHPV-Related CarcinomaHPV-Related Cervical CarcinomaHPV-Related MalignancyHPV-Related Squamous Cell CarcinomaMelanomaNon-small Cell Carcinoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the TCRX page.
See TCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TCRX catalysts and pipeline →